Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Keytruda-Chemo Combo Filed for 1st Line Gastric Cancer in Japan: MSD
MSD said on May 12 that it has filed its PD-1 inhibitor Keytruda (pembrolizumab) in Japan for its label expansion into the first-line treatment of HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with chemotherapy. The submission rides on…
To read the full story
Related Article
- Keytruda Gets Nod for Gastric, Biliary Tract Cancer in Japan
May 20, 2024
- Japan Panel Clears Astellas’ Gastric Cancer Med for Approval after FDA Rejection
March 5, 2024
- Xocova, Astellas’s Gastric Cancer Med Up for PAFSC Review on March 4; Pfizer’s Bispecific, RSV Jab Also on Agenda
February 20, 2024
BUSINESS
- Sanofi Delays Japan Launch of Efluelda by One Year, Defers NIP Rollout
July 22, 2026
- Towa Pins NO2 as Key Driver of Nitrosation, Eyes Lower Filter Costs
July 22, 2026
- FRONTEO Taps Bayer Ex-Chair Eiki as Advisor
July 22, 2026
- JCR Grabs 1st Overseas Nod for Izcargo in UAE
July 22, 2026
- Carna Bio’s AML Drug Candidate Earns US Orphan Tag
July 22, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…